Greater Asia News
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter and provided business updates.
Phyllodulcin Could be a Potential Candidate for Treating Alzheimer’s Disease, Find Sahmyook University Researchers
Assistant Professor Se Jin Jeon of the Department of Integrative Biotechnology, College of Science and Technology, Sahmyook University, along with a group of researchers from Korea, studied the effect of phyllodulcin on Aβ aggregation and various pathological features in an animal model of AD.
SK bioscience Releases 2023 ESG Report, Reaffirming Its Commitment to Sustainability
SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, today released its 2023 Environmental, Social and Governance (ESG) Report.
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023).
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial.
Singapore’s Mirxes to List in Hong Kong After Securing $50M in Series D Funding
Mirxes Holding Company Limited, a Singapore-headquartered biotech firm, announced Tuesday that it has filed listing application with The Stock Exchange of Hong Kong Limited after securing $50 million Series D funding.
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration).
Samsung Biologics Reports Second Quarter 2023 Financial Results
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), today announced financial results for the second quarter of fiscal year 2023.
Dr. Reddy’s Q1 FY24 Financial Results
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2023.
Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders
Astellas Pharma Inc. (TOKYO: 4503, President and CEO: Naoki Okamura, “Astellas”) and PeptiDream Inc. (TOKYO: 4587, President and CEO: Patrick C. Reid, “PeptiDream”) today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas.
